How cool to see Amarantus invest in a new science and technology to help treat concussions. Whats most interesting is that that AMBS is building an empire one day at a time. They are planting the seeds to one day be the next Biotech powerhouse (very talented management team, advisory board, board of directors here). Could we possibly be an Amgen or Celgene? (YES!)
The just locked up P-16 Alzheimers technology with the German outfit and continue to quietly be a VERY diversified company with multiple product lines, technology, a MANF drug and the Phenoguard science (a pure incubator where the next MANF type drug could be spun out any day). If everyone would take some focus away from LymPro and just understand whats coming together; there is a reason why there were HUGE big buys coming back into the stock (as the smart money knows the true underlying value of this company).
We have a Long Term WINNER ....Btw: Cerora is based where I grew up; I would like to learn more about this initiative as it evolves. GLTA!!!!
Proprietary ‘Near the Field’ Objective Concussion Evaluation Technology
BETHLEHEM, PA / ACCESSWIRE / August 1, 2014 / Cerora, Inc., a StartUp Health /GE Healthcare Entrepreneurship program and Ben Franklin Technology Partners of Northeastern Pennsylvania company, today announced a second closing in its seed financing, bringing total funds raised in this round to just above $600,000. This funding will support the commercial launch of Qumpass(TM), the company’s first software product launching this month, and the further development of its Borealis(TM) hardware/software solution for delivering objective brainwave biosensor data to help evaluate concussions right ‘near the field’ of play and in schools for ‘Return-to-Learn’ decision making. Investors in the second closing include The Brewer Group, Inc, Amarantus Bioscience Holdings, Inc. and Marvin S. Cadwell, an experienced health service executive.
"Objective data, rapidly provided near the athletic field would empower field clinicians evaluating concussions with a considerable diagnostic advantage over current assessment techniques," said Adam J. Simon, President & CEO of Cerora. "By empowering field clinicians with objective real-time brain health information, as opposed to subjective clinical impressions, Cerora will improve health outcomes for patients. With these investor commitments to Cerora in hand, our development and commercialization plans can now shift into high gear."
Cerora’s Borealis(TM) multimodal biosensor technology is designed to enable professionals to gather truly objective diagnostic information, which, along with neuropsychological performance data, self-reporting of symptoms, and additional biosensor-based measures, may lead to more accurate determinations. The Company also intends to develop applications of its Borealis(TM) technology for neurodegenerative conditions (such as cognitive impairment and Alzheimer’s disease), developmental conditions (such as Autism), and other brain-affecting conditions where portable, rapid development of objective data can be critical to the early diagnoses that are key to improved patient outcomes.
About Cerora
Cerora is leading the way in the development and testing of the software and hardware technologies (including the Google Glass platform), that will be needed to deliver critically important, objective, portable biomarker-based brain-function diagnostic information to empower health care professionals’ decisions. Located in the high-tech nexus at Ben Franklin Technology Partners of Northeastern Pennsylvania’s TechVentures on Lehigh University’s Mountaintop Campus in Bethlehem, Pennsylvania, the company has assembled a team of experienced scientists and management professionals under the leadership of CEO Adam J. Simon, PhD, a noted physicist and globally-recognized brain biomarker expert.
